Clinical trials: Hepatocellular Carcinoma (HCC), open to volunteers
Advanced Hepatocellular Carcinoma (HCC)
Phase 2 Study of WGI-0301 for Advanced HCC
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have…
- Trial name
- NCT06309485
- Testing
- WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 60 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepatocellular Carcinoma (HCC)
Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical
The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical…
- Trial name
- NCT07815054
- Testing
- Microwave Ablation Assisted by Diaphragm Hydrodissection, Surgical Resection
- Volunteers
- 200 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
HCC - Hepatocellular Carcinoma
Real-world Insight Into Systemic Therapies for HCC: Single-center Study
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies
- Trial name
- HCC (NCT07814014)
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Mansoura University
HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer)
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort
This Vietnam-based observational study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor…
- Conditions
- HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer
- Trial name
- NCT07808164
- Testing
- IHC analysis for ENPP1, cGAS, and FAP expression
- Where
- 2 sites in Vietnam
- Volunteers
- 162 people
- Sponsor
- Tam Anh Research Institute
HCC - Hepatocellular Carcinoma
[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.
The purpose of this study is to evaluate the use of multiparametric dynamic whole-body [68Ga]Ga-PSMA PET/CT imaging in newly diagnosed HCC patients or in HCC patients with recent suspicion of refractory, residual, or recurrent…
- Trial name
- HIMIKO (NCT06999837)
- Testing
- [68Ga]Ga-PSMA-11
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital
HCC - Hepatocellular Carcinoma
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
This study aims to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (the combination antibody) combined with SBRT and Lenvatinib in the perioperative treatment of patients with potentially resectable…
- Trial name
- NCT07801287
- Testing
- Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
This is an open-label, multicenter, randomized controlled Phase II trial. Patients with advanced hepatocellular carcinoma (HCC) who developed secondary resistance to first-line targeted-immunotherapy were randomly assigned to…
- Trial name
- NCT07463248
- Testing
- Tislelizumab Combined With TKI, Fecal Microbiota Transplantation, PULSAR
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Wang Xin
Hepatocellular Carcinoma (HCC)
GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
This is a diagnostic study. This clinical trial aims to evaluate the diagnostic performance and safety of the novel radiotracer 18F-X12 in patients with hepatocellular carcinoma (HCC), and to provide evidence supporting a new…
- Trial name
- NCT07795437
- Testing
- 18F-X12 PET/CT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Hepatocellular Carcinoma (HCC)
SBRT Versus Surgical Resection for Small HCC
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge.
- Trial name
- NCT07381660
- Testing
- Stereotactic body radiotherapy (SBRT), Resection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Sun Yat-sen University
Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis)
Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France.
- Conditions
- Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor
- Trial name
- PreciseOnco (NCT07636148)
- Where
- 3 sites in France, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- Mark C Burgmans, MD PhD
Hepatocellular Carcinoma (HCC)
HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
The investigators propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal…
- Trial name
- NCT07780357
- Testing
- No intervention (observational study)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07551778
- Testing
- NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy
- Volunteers
- 42 people
- Sponsor
- BOE Technology Group Co., Ltd.
Hepatocellular Carcinoma (HCC)
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
- Trial name
- NCT07689175
- Testing
- Nivolumab, Ipilimumab (3 mg/kg)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma (HCC)
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy.
- Trial name
- NCT07782632
- Testing
- Baseline Liver Volume Volumetric Analysis
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma (HCC), Radioembolization
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a…
- Trial name
- BEAT-UT7 (NCT06773845)
- Testing
- TheraSphere
- Where
- 8 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Hepatocellular Carcinoma (HCC)
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
This is a Phase 2, open-label, single-arm, multicenter study designed to evaluate the safety and efficacy of atezolizumab, bevacizumab, and tocilizumab in patients with locally advanced, metastatic, and/or unresectable…
- Trial name
- AB-TCZ (NCT07774247)
- Testing
- Atezolizumab, Bevacizumab, Tocilizumab
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- CHA University